17 February 2022 - First TGA approval for newcomer Apellis.

Pegcetacoplan (Empaveli) is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria who have an inadequate response to, or are intolerant of, a C5 inhibitor.

Read TGA prescription medicine decision summary for Empaveli